Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Daraxonrasib (Primary) ; Elironrasib (Primary) ; Ivonescimab (Primary) ; Pemetrexed (Primary) ; Zoldonrasib (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms APEX103
  • Sponsors REVOLUTION Medicines

Most Recent Events

  • 30 Apr 2026 According to a Summit Therapeutics media release, enrollment of patients began in the first quarter of 2026.
  • 13 Feb 2026 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top